Evaporate 9 billion a day!"Yao Mao" flapped the limit, the institution staged a fugitive, and the company responded to the storm

On August 18th, due to the news of the growth hormone in Zhejiang, the "Yao Mao" Changchun High -tech afternoon crashed and fell, and the stock price reported that it fell at 202.1 yuan/share. On the evening of the same day, according to the post -trading information disclosed by the Shenzhen Stock Exchange's official website, the institution staged the "Battle Royale" and sold a total of 377 million yuan.

Image source: Screenshot of Oriental Fortune Data

The transaction market shows that on August 18, Changchun High -tech opened a slightly lower 0.79%low, and the company maintained a low shocking trend throughout the day. After 2 pm, multiple selling orders appeared, and Changchun High -tech stocks quickly collapsed. As of the closing of the day, Changchun High -tech failed to open the limit board. The company's stock price was reported at 202.1 yuan/share, with a turnover of 2.427 billion yuan, a renewal rate of 3%, and a total market value of 81.79 billion yuan.

On the previous trading day, the total market value of Changchun High -tech was 90.88 billion yuan. After calculation, in just one trading day, the company's total market value evaporated by 9.09 billion yuan.

Image source: Screenshot of the Shenzhen Stock Exchange's official website

On the evening of August 18th, the Shenzhen Stock Exchange disclosed the post -trading information of the day, including one, three, three, and fifth of the fifth of the institution, which were sold for 154 million yuan, 125 million yuan, and 72.3818 million yuan, respectively. , 53.8137 million yuan, the purchase amount is 0. In addition, the buying five seats is also a special seat for institutions. The purchase amount is 27.7935 million yuan, and the selling amount is 0.

According to the Beijing Commercial Daily reporter, Changchun High -tech was sold by four institutions for a total of 405 million yuan, and a total of 377 million yuan was sold by the institution.

Behind Changchun's high -tech stock price, behind the decline, it mainly comes from a market news. On August 18th, the Pharmaceutical Medical Consumption Consumer Procurement Office of Zhejiang Province formulated the "Third Batch of Pharmaceutical Purchase Procurement Documents in Zhejiang Public Medical Institutions" (draft for comments). According to market news, although the procurement directory has not been announced to the public, some of them are the main product growth hormones of Changchun High -tech.

In response to the above news, Changchun High -tech investors also asked questions on the interactive platform. Regarding the question of "whether the company has received a specific official document of Zhejiang Ji Cai, if it is received, is there a specific collection plan for growth hormones?" The company did not receive the relevant formal notice. For growth hormone collection, from the current episodes of the existing Guangdong Alliance, it has not had a negative impact on the sales of the company's growth hormone products. At the same time Market coverage.

Pharmaceutical expert Wei Zimeng told a reporter from Beijing Business Daily that if the company's growth hormone products were included in the collection, in terms of business, it would have a certain impact on the company's performance, but how the impact should be analyzed in detail.

A reporter from Beijing Commercial Daily noticed that this is not the first time in Changchun High -tech this year to face the storm. In January of this year, the company's growth hormone products have been included in the drug collection of Guangdong Province. In response to related issues, the reporter called Changchun High -tech Directors' Office to conduct an interview, but no one answered the phone.

The reason why the above news has a greater impact on Changchun's high -tech is because the growth hormone business accounts for a higher company revenue.

According to the data, the main business of Changchun High -tech is the research and development, production and sales of biopharmaceuticals and proprietary Chinese medicines, supplemented by real estate development, property management and services. The research and development, production and sales of biomedicals, the main products are the growth hormone (pink acupuncture hormone injection (water needle) (water needle) and so on.

Picture source: Changchun High -tech annual report of 2021

Judging from the revenue in 2021, Changchun High -tech achieved operating income of about 10.75 billion yuan in that year, and the operating income of Jincai Pharmaceutical was about 8.198 billion yuan. Calculated by the Beijing Commercial Daily reporter, the subsidiary Jin Sai Pharmaceutical's contribution to Changchun High -tech revenue was as high as 76.26%.

In the first quarter of this year, Changchun High -tech achieved double revenue and net profit increase. Among them, operating income was approximately 2.975 billion yuan, an increase of 30.4%year -on -year; the corresponding net profit attributable to was about 1.138 billion yuan, an increase of 30.16%year -on -year. For the performance of the first half of this year, Changchun High -tech is expected to disclose it on August 26.

Reporter 丨 horse replacement

Edit 丨 Zhang Lan

Photo 丨 Changchun High -tech annual report screenshot, Shenzhen Stock Exchange official website screenshot, Oriental wealth data screenshot, visual China

- END -